Stu Needleman, Chief Commercial Officer at Piramal Pharma Solutions, discusses the Biosecure Act and other big trends shaking up the industry, including GLP-1s, consolidation in the CDMO sector, and sterile fill-finish. He tells us more about Piramal’s $80-million expansion in Kentucky and how the company is adapting to the changes in the market. Check out the video!
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
April 11, 2025
3 min read
In the ever volatile, highly regulated precision medicine development sector, the agility and expertise of a CDMO can make or break a commercial drug candidate.
March 6, 2025
3 min read
And getting the right people involved from the start. Here’s why collaboration is key for successful clinical development.
March 10, 2025
3 min read
From geopolitical conflicts to cyber threats, CDMOs must rethink resilience.
March 26, 2025
3 min read
With competition for skilled employees in cell and gene therapy manufacturing high, companies need to ensure they are investing in training and mentorship.